{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:23:43Z","timestamp":1783445023034,"version":"3.54.6"},"reference-count":13,"publisher":"Bioscientifica","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":869,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A 73-year-old woman with type 2 diabetes mellitus was referred to our department for glycaemic control. Physical examination revealed two subcutaneous hard masses around the left shoulder and the right hip joint. The patient could not fully extend her fingers because of skin sclerosis in both hands. Laboratory studies showed hyperphosphataemia and a high ratio of renal tubular maximum reabsorption of phosphate to glomerular filtration rate. There were no abnormalities in serum calcium, creatinine, alkaline phosphatase, and intact parathyroid hormone levels, whereas serum fibroblast growth factor 23 was low. Hyperphosphataemic familial tumoural calcinosis\/hyperostosis-hyperphosphataemia syndrome (HFTC\/HHS) was diagnosed using whole genome sequencing that revealed a novel frameshift beyond the 584th threonine located in the lectin domain of UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 associated with a duplication of the 1748th thymine in the coding region of the corresponding gene. Furthermore, anti-nuclear, anti-centromere, and anti-cardiolipin antibodies were positive, implying that comorbid limited type scleroderma might play a role in tumoural calcinosis (TC) development. A low phosphate diet was prescribed with phosphate-lowering medications, including aluminium hydroxide, acetazolamide, and sevelamer hydrochloride. The patient displayed a decrease in serum phosphate levels from 6.5 to 5.5 mg\/dL 10 months after the initiation of treatment, but her TC had not improved during treatment for more than 1 year. This case was interesting because the patient with HFTC\/HHS exhibited TC despite being over her 60s, and subsequent scleroderma might contribute to the specific clinical course. When HFTC\/HHS presents with elderly-onset TC, the involvement of comorbidities in exacerbating TC should be considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Learning points<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1530\/edm-23-0071","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T10:06:01Z","timestamp":1696327561000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":1,"title":["Elderly-onset calcinosis of hyperphosphataemic familial tumoural calcinosis\/hyperostosis-hyperphosphataemia syndrome: the role of comorbid scleroderma"],"prefix":"10.1530","volume":"2023","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0029-6003","authenticated-orcid":true,"given":"Hiroaki","family":"Iwasaki","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism 1","department":["Department of Internal Medicine, Toshiba Rinkan Hospital, Sagamihara, Kanagawa, Japan"]},{"name":"Division of Endocrinology and Metabolism 2","department":["Department of Internal Medicine, Minamiyamato Hospital, Yamato, Kanagawa, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2023,10,3]]},"reference":[{"key":"2026070712314939300_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ad.2015.09.001","article-title":"Calcinosis cutis and calciphylaxis","volume":"106","author":"Jim\u00e9nez-Gallo","year":"2015","journal-title":"Actas Dermo-Sifiliograficas"},{"key":"2026070712314939300_bib2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"2026070712314939300_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00223-020-00659-6","article-title":"Congenital hyperphosphatemic conditions caused by the deficient activity of FGF23","volume":"108","author":"Ito","year":"2021","journal-title":"Calcified Tissue International"},{"key":"2026070712314939300_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fendo.2020.00293","article-title":"Hyperphosphatemic tumoral calcinosis: pathogenesis, clinical presentation, and challenges in management","volume":"11","author":"Boyce","year":"2020","journal-title":"Frontiers in Endocrinology"},{"key":"2026070712314939300_bib5","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/jbmr.2870","article-title":"Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis\/hyperostosis-hyperphosphatemia syndrome","volume":"31","author":"Ramnitz","year":"2016","journal-title":"Journal of Bone and Mineral Research"},{"key":"2026070712314939300_bib6","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00198-018-4574-x","article-title":"Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature","volume":"29","author":"Chakhtoura","year":"2018","journal-title":"Osteoporosis International"},{"key":"2026070712314939300_bib7","doi-asserted-by":"crossref","first-page":"e10470","DOI":"10.1002\/jbm4.10470","article-title":"A cross-sectional cohort study of the effects of FGF23 deficiency and hyperphosphatemia on dental structures in hyperphosphatemic familial tumoral calcinosis","volume":"5","author":"Lee","year":"2021","journal-title":"JBMR Plus"},{"key":"2026070712314939300_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41589-019-0444-x","article-title":"Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3","volume":"16","author":"de Las Rivas","year":"2020","journal-title":"Nature Chemical Biology"},{"key":"2026070712314939300_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1529-8019.2012.01492.x","article-title":"Calcinosis cutis in autoimmune connective tissue diseases","volume":"25","author":"Gutierrez","year":"2012","journal-title":"Dermatologic Therapy"},{"key":"2026070712314939300_bib10","first-page":"223","article-title":"Clinical characteristics in patients with systemic sclerosis and symptomatic subcutaneous calcinosis","volume":"5","author":"Shirai","year":"2020","journal-title":"Journal of Scleroderma and Related Disorders"},{"key":"2026070712314939300_bib11","first-page":"259","article-title":"Role of fibroblast growth factor-23 in calcinosis in women with systemic sclerosis","volume":"45","author":"Cantero-Nieto","year":"2020","journal-title":"Acta Reumatologica Portuguesa"},{"key":"2026070712314939300_bib12","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"2026070712314939300_bib13","first-page":"171","article-title":"Association between calciphylaxis and inflammation in two patients on chronic dialysis","volume":"22","author":"Slough","year":"2006","journal-title":"Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2023\/4\/EDM23-0071.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2023\/4\/EDM23-0071.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/edm\/article-pdf\/doi\/10.1530\/EDM-23-0071\/26616\/edm23-0071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/edm\/article-pdf\/doi\/10.1530\/EDM-23-0071\/26616\/edm23-0071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:31:54Z","timestamp":1783441914000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/edm\/article\/2023\/4\/23-0071\/3656\/Elderly-onset-calcinosis-of-hyperphosphataemic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1530\/edm-23-0071","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,1]]},"article-number":"23-0071"}}